MediPharm Labs Corp. MEDIF OTC

Other OTC • Healthcare • Drug Manufacturers - Specialty & Generic • CA • USD

SharesGrow Score

43/100

1/5 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

MediPharm Labs Corp. (MEDIF) , forward earnings yield 769.23%.

Criteria proven by this page:

VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Forward P/E 0.1

Overall SharesGrow Score: 40/100 with 1/7 criteria passed.

SharesGrow 7-Criteria Score

43/100

SG Score

View full scorecard →

—

VALUE

N/A

No coverage

—

FUTURE

N/A

No coverage

✗

PAST

0/100

→ Income

HEALTH

67/100

Debt-to-Equity & liquidity

→ Health

✗

MOAT

36/100

→ Income

✓

GROWTH

100/100

→ Income

✗

INCOME

10/100

→ Income

Valuation Snapshot — MEDIF

Valuation Multiples

P/E (TTM)0.0

Forward P/E0.1

PEG RatioN/A

Forward PEGN/A

P/B Ratio0.00

P/S Ratio0.47

EV/EBITDA0.0

Per Share Data

EPS (TTM)$-0.03

Forward EPS (Est.)$0.37

Book Value / Share$0.00

Revenue / Share$0.10

FCF / Share$0.00

Yields & Fair Value

Earnings YieldN/A

Forward Earnings Yield769.23%

Dividend Yield0.00%

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year	EPS (Diluted)	Revenue	Net Income	Net Margin
2017	$0.00	$0.00	$0.00	-
2018	$-0.12	$10.2M	$-8.39M	-82.2%
2019	$0.01	$129.25M	$1.13M	0.9%
2020	$-0.48	$36.01M	$-67.11M	-186.4%
2021	$-0.22	$21.71M	$-54.8M	-252.4%
2022	$-0.11	$22.12M	$-29.98M	-135.6%
2023	$-0.04	$33.06M	$-13.08M	-39.6%
2024	$-0.03	$41.96M	$-10.69M	-25.5%